Ambee Pharmaceuticals PLC

DSE:AMBEEPHA Stock Report

Market Cap: ৳1.7b

Ambee Pharmaceuticals Past Earnings Performance

Past criteria checks 1/6

Ambee Pharmaceuticals has been growing earnings at an average annual rate of 33.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 6.6% per year. Ambee Pharmaceuticals's return on equity is 31.9%, and it has net margins of 4.3%.

Key information

33.1%

Earnings growth rate

33.1%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate-6.6%
Return on equity31.9%
Net Margin4.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ambee Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DSE:AMBEEPHA Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24232101110
30 Jun 24219101040
31 Mar 2420511970
31 Dec 2320911990
30 Sep 2320810980
30 Jun 231989920
31 Mar 2319110870
31 Dec 221809820
30 Sep 221868850
30 Jun 221818830
31 Mar 22134-13640
31 Dec 21136-13650
30 Sep 21109-13520
30 Jun 2199-13480
31 Mar 21147-1740
31 Dec 201881960
30 Sep 2024121180
30 Jun 2028541400
31 Mar 2031131450
31 Dec 1931631470
30 Sep 1931331460
30 Jun 1932131490
31 Mar 1933681610
31 Dec 1834491660
30 Sep 1834781670
30 Jun 1834981660
31 Mar 1835081610
31 Dec 1735281590
30 Sep 1735581600
30 Jun 1735271590
31 Mar 1735251680
31 Dec 1633741600
30 Sep 1634031600
30 Jun 1634151600
30 Sep 1534871540
30 Jun 1536681670
31 Mar 1534971580
31 Dec 1434481560

Quality Earnings: AMBEEPHA has a high level of non-cash earnings.

Growing Profit Margin: AMBEEPHA's current net profit margins (4.3%) are lower than last year (4.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AMBEEPHA's earnings have grown significantly by 33.1% per year over the past 5 years.

Accelerating Growth: AMBEEPHA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AMBEEPHA had negative earnings growth (-0.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.3%).

Return on Equity

High ROE: Whilst AMBEEPHA's Return on Equity (31.89%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 03:53
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ambee Pharmaceuticals PLC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution